TITLE

Subsets of CD34+ and early engraftment kinetics in allogeneic peripheral SCT for AML

AUTHOR(S)
Pastore, D.; Mestice, A.; Perrone, T.; Gaudio, F.; Delia, M.; Albano, F.; Russo Rossi, A.; Carluiccio, P.; Leo, M.; Liso, V.; Specchia, G.
PUB. DATE
June 2008
SOURCE
Bone Marrow Transplantation;Jun2008, Vol. 41 Issue 11, p977
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This study aimed to identify which graft product subset of CD34+ cells might be the most predictive of early hematopoietic recovery following allogeneic peripheral SCT (allo-PBSCT). The relationship between the number of �mature� subsets of CD34+ cells (CD34+/CD33+, CD34+/CD38+, CD34+/DR+ and CD34+/CD133-) and �immature� subsets of CD34+ cells (CD34+/CD33-, CD34+/CD38-, CD34+/DR- and CD34+/CD133+) and early neutrophil and platelet engraftment were studied in a homogeneous series (for disease, pre transplant chemotherapy, conditioning regimen and GVHD prophylaxis) of 30 AML patients after allo-PBSCT from HLA-identical siblings. In our experience, the total CD34+/CD133+ cell number was inversely correlated with the days required for the recovery of 0.5 � 109/l neutrophils (r=-0.82, P=0.02) and platelets of 20 � 109/l (r=-0.60, P=0.06); this correlation was better than the total CD34+ cell dose and neutrophil (r=-0.70, P=0.04) and platelet engraftment (r=-0.56, P=0.07). We suggest that a high number of CD34+/CD133+ PBSC may be associated with faster neutrophil and platelet recovery; these findings may help to predict the repopulating capacity of PBSC in patients after allo-PBSCT, especially when a relatively low number of CD34+ cells is infused.Bone Marrow Transplantation (2008) 41, 977�981; doi:10.1038/bmt.2008.87; published online 21 April 2008
ACCESSION #
32566153

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics